Pharmaceutical composition for keratosis and use thereof
A pharmaceutical composition for keratosis contains 5-methyl-2-(1-piperazinyl)benzenesulfonic acid. The compound may be in a form of an anhydrate thereof, a salt thereof, a hydrate or solvate thereof, or a hydrate or solvate of a salt thereof, and the hydrate is, for example, 5-methyl-2-(1-piperazinyl)benzenesulfonic acid monohydrate. The keratosis is, for example, Darier's disease or psoriasis.
1 . A method for treating Darier's disease, comprising:
administering an effective amount of a pharmaceutical composition comprising 5-methyl-2-(1-piperazinyl)benzenesulfonic acid to a subject in need thereof.
2 . The method of claim 1 , wherein the pharmaceutical composition is orally administered to the subject in need thereof.
3 . The method of claim 1 , wherein the pharmaceutical composition is parenterally administered to the subject in need thereof.
4 . The method of claim 1 , wherein the pharmaceutical composition is administered to the subject in need thereof such that a dosage of the 5-methyl-2-(1-piperazinyl)benzenesulfonic acid is in a range of 1 to 1000 mg/day.
5 . The method of claim 2 , wherein the pharmaceutical composition is administered to the subject in need thereof such that a dosage of the 5-methyl-2-(1-piperazinyl)benzenesulfonic acid is in a range of 1 to 1000 mg/day.
6 . The method of claim 3 , wherein the pharmaceutical composition is administered to the subject in need thereof such that a dosage of the 5-methyl-2-(1-piperazinyl)benzenesulfonic acid is in a range of 1 to 1000 mg/day.
7 . The method of claim 1 , wherein the pharmaceutical composition is administered to the subject in need thereof such that at least one of hyperkeratosis in a stratum corneum, a granular layer and a spinous layer, dyskeratosis in a spinous layer, and acantholysis in a spinous layer is suppressed.
8 . The method of claim 1 , wherein the pharmaceutical composition is administered daily to the subject in need thereof.
9 . The method of claim 1 , wherein the pharmaceutical composition is administered to the subject in need thereof in a range of 1 to 3 times per day.
10 . The method of claim 1 , wherein the subject in need thereof is a patient in need thereof.
11 . The method of claim 4 , wherein the pharmaceutical composition is administered to the subject in need thereof such that at least one of hyperkeratosis in a stratum corneum, a granular layer and a spinous layer, dyskeratosis in a spinous layer, and acantholysis in a spinous layer is suppressed.
12 . The method of claim 4 , wherein the pharmaceutical composition is administered daily to the subject in need thereof.
13 . The method of claim 4 , wherein the pharmaceutical composition is administered to the subject in need thereof in a range of 1 to 3 times per day.
14 . The method of claim 4 , wherein the subject in need thereof is a patient in need thereof.
15 . The method of claim 1 , wherein the pharmaceutical composition is administered to the subject in need thereof such that a dosage of the 5-methyl-2-(1-piperazinyl)benzenesulfonic acid is in a range of 10 to 500 mg/day.
16 . The method of claim 1 , wherein the pharmaceutical composition is administered to the subject in need thereof such that a dosage of the 5-methyl-2-(1-piperazinyl)benzenesulfonic acid is in a range of 100 to 400 mg/day.
17 . The method of claim 2 , wherein the pharmaceutical composition is administered to the subject in need thereof such that a dosage of the 5-methyl-2-(1-piperazinyl)benzenesulfonic acid is in a range of 10 to 500 mg/day.
18 . The method of claim 2 , wherein the pharmaceutical composition is administered to the subject in need thereof such that a dosage of the 5-methyl-2-(1-piperazinyl)benzenesulfonic acid is in a range of 100 to 400 mg/day.
19 . The method of claim 10 , wherein the pharmaceutical composition is administered to the patient in need thereof such that a dosage of the 5-methyl-2-(1-piperazinyl)benzenesulfonic acid is in a range of 10 to 500 mg/day.
20 . The method of claim 10 , wherein the pharmaceutical composition is administered to the patient in need thereof such that a dosage of the 5-methyl-2-(1-piperazinyl)benzenesulfonic acid is in a range of 100 to 400 mg/day.